Jubilant Biosys, a Bengaluru based subsidiary of Jubilant Life Sciences, announced today that it has expanded its drug discovery alliance with Janssen Pharmaceutica N.V., Beerse, Belgium. The alliance was forged initially in the year 2011 and aims to deliver preclinical candidates to Janssen. The new agreement into multiple therapeutic areas has been expanded owing to Jubilant’s diversified skill sets in various therapeutic areas. Most of the research will be undertaken at Jubilant Biosys, India and some parts at Jubilant Discovery Center, USA.
Janssen Pharmaceutica, Belgium is part of the ‘Janssen Pharmaceutical Companies of Johnson & Johnson’. The collaboration between the two organizations has been expanded to leverage Jubilant’s drug discovery capabilities on selected drug discovery targets to advance programs in multiple disease areas. Jubilant will carry out research services and will deliver preclinical candidates to Janssen for potential development and commercialization. In addition to research funding, Jubilant will also receive milestones and royalties should Janssen successfully progress the assets into clinical development and commercialization.
“We are pleased to announce the expansion of the Janssen- Jubilant collaboration and look forward to discovering Novel Chemical Entities (NCE’s) that address the unmet medical needs in these important disease areas", said Dr. Subir K. Basak, President, Jubilant Biosys (Global Drug Discovery Services)”. Over the past several years, we have been strengthening our disease franchises from a scientific perspective, and this collaboration serves as a validation of those efforts. We look forward to a long, and mutually beneficial, partnership.”
Jubilant provides comprehensive drug discovery solutions from target discovery to IND in partnership with leading healthcare companies worldwide, offering integrated & collaborative drug discovery services across early discovery, synthetic and medicinal chemistry including scale up and pre-clinical services. Jubilant houses eminent scientists who carry with them rich experience from global pharmaceutical companies and academic institutions. The company is one of the leading service providers in Protein X-Ray crystallography in India, which in combination with medicinal chemistry and computational chemistry provides a powerful Structure Based Drug Design platform and a best niche platform to build and drive Structure Activity Relationship (SAR) for various discovery programs. Jubilant has been a partner to some of the major large and mid-size pharma and Biotech companies.
About Jubilant Biosys Ltd.:
Jubilant Biosys Ltd. is a Bengaluru based subsidiary of Jubilant Life Sciences Ltd, headquartered in Noida, India. Jubilant Biosys, is a leading provider of integrated drug discovery solutions to the global pharmaceutical industry. Biosys has pioneered the risk shared collaborative discovery model and has a demonstrated track record of placing assets in the clinic via multiple partnerships in the therapeutic areas of Oncology, Metabolic Disorders, Pain & Inflammation, CNS and others. Learn more about us at www.jubilantbiosys.com
About Jubilant Life Sciences:
Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients. It also provides services in Contract Manufacturing of Sterile Injectables and Ointments, Creams and Liquids and Drug Discovery and Development. The Company’s strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of over6300 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 100 countries. The Company is well recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies globally. For more info, visit www.jubl.com
About Janssen Pharmaceutica
Janssen Pharmaceutica is a part of the worldwide Janssen Pharmaceutical Group of Johnson and Johnson. Janssen Pharmaceutica is one of the most innovative pharmaceutical companies in the world and the Janssen research and development centre develops products for a wide range of disease areas, such as mental disorders, neurological problems, infectious diseases, immunological disorders, cancer, and cardiovascular and metabolic conditions.
For more info, visit www.janssenpharmaceutica.be